Features
Questions Every Law Firm Leader Should Be Asking
In a legal marketplace transformed by technology, heightened client expectations, and fierce competition, law firm leaders must approach strategy with rigor and clarity. The following questions, accompanied by relevant statistics and explanations, offer a focused guide for uncovering opportunity and driving sustainable growth.
Features
5 Operational Foundations That Determine Whether Your Tech Investments Will Succeed In 2026
The difference between technology investments that succeed and those that fail may have less to do with the tools themselves than the operational foundation beneath them.
Features
5 Reasons Law Firms Keep Undervaluing Their Administrative Backbone and How to Fix It
The firms investing in administrative strategy — and in the people who embody it — continue to be the ones turning innovation into true competitive advantage.
Features
Private Equity Companies Look to Continue Inroads In Legal By Funding Lateral Partner Moves
Private equity companies, which have successfully made inroads into the legal industry, are now considering funding lateral partner moves to bring top rainmakers to midtiered firms that might not otherwise have the compensation flexibility to land top names, experts say.
Features
Does the Corporatization of Big Law Mean the End of the Law Firm Partnership?
By definition, equity partners are law firm owners and investors, share in the profits, and are collectively responsible for overall strategy and management. Yet, when only a handful of people are involved in a monumental decision such as a merger, it’s clear that the definition of “partnership” has changed.
Features
What Award-Winning Firms Know About Equipment Strategy
Technology infrastructure now defines how law firms deliver service, manage compliance, and compete for clients. The most forward-looking firms are not just upgrading systems; they are transforming how they plan, finance, and govern their technology investments.
Features
The Impact of Washington’s Sales Tax Law Changes for Professional Service Firms
Washington state expanded the breadth of its sales tax laws, which could catch professional service firms off guard. While traditional legal and accounting services are exempt from sales tax, the ripple effects of this change could still substantially impact professional services firms, albeit in subtle but significant ways.
Features
Charitable Giving Under The OBBBA: Strategic Tax Planning for High-Net-Worth Individuals
The One Big Beautiful Bill Act (OBBBA), enacted on July 4, 2025, introduces sweeping reforms to the tax treatment of charitable contributions. For high-net-worth individuals (HNWIs), these changes present both strategic opportunities and new limitations that warrant careful planning to preserve philanthropic impact and optimize tax outcomes.
Features
From First Impression to Lasting Reputation: The Case for Etiquette Training In Your Law Firm
The mandatory work-from-home period, followed by hybrid schedules, has caused many professionals to lose sight of common courtesies and the fundamental standards of good etiquette that once guided workplace interactions. I encourage you to take a close look around your firm — observe how partners, associates, and staff communicate with one another. What you see and hear may confirm the need to intentionally rebuild a culture of respect and professionalism. Here is a list to help with your observations.
Features
Tensions Building Over AI Billing
AI may be accelerating legal work, but it’s also escalating tensions over how that work gets billed — and who benefits from the time saved.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- Surveys in Patent Infringement Litigation: The Next FrontierMost experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.Read More ›
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- In the SpotlightOn May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug & Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.Read More ›
